Five Prime Therapeutics, Inc.

Aduro Gvax Inc.

Cell Genesys, Inc.

Biosante Pharmaceuticals, Inc.

Thomas Harding

Karin Ute Jooss

Minh Nguyen

Kathryn E Koprivnikar

W Michael Kavanaugh

Thomas Brennan

Kevin Hestir

Li Long

Julie Hambleton

Servando Palencia

Kristen Pierce

Namrata Patil

Brian Donahue

Alshad Lalani

Michael W Kavanaugh

The present invention provides antibodies that bind FGFR2IIIb, wherein the antibodies are afucosylated. The present invention provides compositions comprising antibodies that bind FGFR2IIIb, wherein at least 95% of the antibodies in the composition are afucosylated. In some embodiments, methods of treating cancer comprising administering afucosylated anti-FGFR2IIIb antibodies are provided.

Afucosylated anti-FGFR2IIIB antibodies

Methods of treating cancers comprising FGFR1 gene amplification are provided. In some embodiments, the methods comprise administering a fibroblast growth factor receptor 1 (FGFR1) extracellular domain (ECD) and/or an FGFR1 ECD fusion molecule. In some embodiments, the methods comprise administering a fibroblast growth factor receptor 1 (FGFR1) extracellular domain (ECD) and/or an FGFR1 ECD fusion molecule in combination with at least one additional therapeutic agent.

Methods of treating lung cancer

Method of treatment of malignant solid tumors with afucosylated anti-FGFR2IIIb antibodies

The present invention relates to prostate cancer markers, compositions comprising such markers, and methods of using such markers to induce or increase an immune response against prostate cancer. An immune response against the markers correlates with an immune response, in particular a humoral immune response, against prostate cancer cells which immune response is preferably associated with prophylaxis of prostate cancer, treatment of prostate cancer, and/or amelioration of at least one symptom associated with prostate cancer.

Methods and compositions for treating prostate cancer or inducing a humoral immune response against prostate cancer

The present invention relates to the use of Fibroblast Growth Factor Receptor I (FGFR1) extracellular domain (ECD) polypeptides for treatment of cancers characterized by ligand dependent activating mutations in Fibroblast Growth Factor Receptor 2 (FGFR2). For example, the present invention relates to the treatment of endometrial cancers and other cancers wherein tumor cells express FGFR2 mutants in the IgII-IgIII hinge region or IgIII domain of the protein, such as at amino acid positions 252 and/or 253.

Method of treatment of cancers characterized by ligand-dependent activating mutations in FGFR2 with FGFR1 ECD proteins

Use of FGFR1 extra cellular domain proteins to treat cancers characterized by ligand-dependent activating mutations in FGFR2

The present invention relates to prostate cancer markers, compositions comprising such markers, immunoglobulins specific for such markers, and methods of using such markers and/or immunoglobulins to assess an immune response against prostate cancer. An immune response against the markers correlates with an immune response, in particular a humoral immune response, against prostate cancer cells which immune response is preferably associated with prophylaxis of prostate cancer, treatment of prostate cancer, and/or amelioration of at least one symptom associated with prostate cancer.

Methods and compositions for identifying prostate cancer or a humoral immune response against prostate cancer

The present invention provides therapeutic compositions and methods for vector-mediated delivery and in vivo expression of polynucleotides encoding anti-cancer compounds that are effective in the treatment of cancer. In particular, the invention relates to the use of recombinant viral and non-viral vectors to deliver genes encoding one or more anti-angiogenic or proapoptotic gene products for the treatment of cancer.

Method for treating cancer by vector-mediated delivery of one or more anti-angiogenic or pro-apoptotic genes

Growing community of inventors

San Francisco, CA, United States of America

Thomas Harding